In Brief: Omlyclo — An Omalizumab Biosimilar Interchangeable with Xolair
Omlyclo (omalizumab-igec; Celltrion), a biosimilar product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair, has been approved by the FDA for same indications as Xolair (see Table 1). Omlyclo is the first Xolair biosimilar to be approved in the US.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2025-06-09
- DOI
- https://doi.org/10.58347/tml.2025.1730f
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00